Zelira Therapeutics Limited (FRA:G1G)

Market Cap	3.59M -16.6%
Revenue (ttm)	366.00 -99.3%
Net Income	-2.03M
EPS	-0.18
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.3000
Previous Close	0.3040
Day's Range	0.3000 - 0.3000
52-Week Range	0.1670 - 0.5100
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Zelira Therapeutics

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment product...

• Industry: Pharmaceutical Preparations
• Founded: 2003
• Country: Australia
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: G1G

Financial Performance

In fiscal year 2025, Zelira Therapeutics's revenue was 656, a decrease of -99.31% compared to the previous year's 94,952. Losses were -3.63 million, -90.08% less than in 2024.

Financial numbers in AUD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 27, 2026

Data Sources Report a data error